Nathan C. Hall MD, PhD

Nathan C. Hall MD, PhD
Assoc ProfessorCollege of Medicinehall.491@osu.edu
432 Doan Hall 395 W 12th Avenue Columbus Ohio 43210
Phone:614-293-2788Fax: 614-293-9275
  • Translational Therapeutics

General Research Interest

Dr. Hall’s research interests include state-of-the-art image processing, reconstruction and quantification methods, PET/CT, MRI/PET and SPECT/CT. Kinetic modeling with dynamic imaging is also an area of interest. The over goal is to better determine ways to increase the sensitivity, specificity and accuracy of molecular imaging.

Research Description

The main focus of Dr. Hall’s efforts involve utilizing molecular imaging techniques to improve the management and care of cancer patients. Projects involve improving quantification for therapy response assessment, as well as, developing imaging techniques for use in the intra and perioperative setting to improve the care and outcome of surgical oncology patients.

Transinstitutional Work

Transinstitutional efforts have led to research collaborations with the Department of Opthomology, Department of Surgery, Department of Pathology and the Ohio State College of Veterinary Medicine.  We have an interdisciplinary research project designed around intraoperative imaging for better localization as well as verification of resection and improvement of pathology sampling in surgical oncology patients that involves Radiology, Surgery and Pathology.  I am the Co-Advisor for a PhD student in Biophysics as well.

Current Publications

  • Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KAComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.Cancer 120 1677-85 6/1/2014
  • Povoski SP, Murrey DA, Smith SM, Martin EW, Hall NC18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.BMC Cancer 14 453 1/1/2014
  • Marcinow AM, Hall N, Byrum E, Teknos TN, Old MO, Agrawal AUse of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study.JAMA Otolaryngol Head Neck Surg 139 895-902 9/1/2013
  • Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM, Flynn J, Andritsos LA, Devine SM, Blum KAAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant 48 1212-7 9/1/2013
  • La Perle KM, Kim DC, Hall NC, Bobbey A, Shen DH, Nagy RS, Wakely PE, Lehman A, Jarjoura D, Jhiang SMModulation of sodium/iodide symporter expression in the salivary gland.Thyroid 23 1029-36 8/1/2013
  • Wallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, Hoh CK, Limmer KK, Krontiras H, Frazier TG, Cox C, Avisar E, Faries M, King DW, Christman L, Vera DRComparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials.Ann Surg Oncol 20 2590-9 8/1/2013
  • Hall NC, Povoski SP, Zhang J, Knopp MV, Martin EWUse of intraoperative nuclear medicine imaging technology: strategy for improved patient management.Expert Rev Med Devices 10 149-52 3/1/2013
  • Povoski SP, Hall NC, Murrey DA, Sharp DS, Hitchcock CL, Mojzisik CM, Bahnson EE, Knopp MV, Martin EW, Bahnson RRMultimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma.Surg Innov 20 59-69 2/1/2013
  • Povoski SP, Chapman GJ, Murrey DA, Lee R, Martin EW, Hall NCIntraoperative detection of ¹⁸F-FDG-avid tissue sites using the increased probe counting efficiency of the K-alpha probe design and variance-based statistical analysis with the three-sigma criteria.BMC Cancer 13 98 1/1/2013
  • Povoski SP, Hall NCRecognizing the role of surgical oncology and cancer imaging in the multidisciplinary approach to cancer: an important area of future scholarly growth for BMC Cancer.BMC Cancer 13 355 1/1/2013
  • Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DMFractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.Cancer 118 5497-506 11/15/2012
  • Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD, Cancer Leukemia Group BInterim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?Leuk Lymphoma 53 2143-50 11/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu